Autocrine production of interleukin 6 causes multidrug resistance in breast cancer cells - PubMed (original) (raw)
. 2001 Dec 15;61(24):8851-8.
Affiliations
- PMID: 11751408
Autocrine production of interleukin 6 causes multidrug resistance in breast cancer cells
D Conze et al. Cancer Res. 2001.
Abstract
It has been shown that serum levels of interleukin (IL)-6 are elevated in patients with various types of cancer. However, the exact source of IL-6 in these patients and its role in tumor progression remain unclear. Here we demonstrate that the autocrine production of IL-6 by tumor cells promotes resistance of the cells to chemotherapy, a novel function of IL-6 in cancer biology. Breast cancer cells that are sensitive to drug treatment do not express IL-6, whereas high levels of IL-6 are produced by multidrug-resistant breast cancer cells. Expression of the IL-6 gene in drug-sensitive breast cancer cells increases their resistance to drug treatment by activating the CCAAT enhancer-binding protein family of transcription factors and inducing mdr1 gene expression. Thus, the autocrine production of IL-6 by tumor cells is an important factor in determining the susceptibility or resistance of these cells to drug treatment. Because tumors from some breast cancer patients contain IL-6-producing cells, it is possible that IL-6 could potentially be used as a prognostic factor for chemotherapy resistance.
Similar articles
- Cyclooxygenase-2, P-glycoprotein-170 and drug resistance; is chemoprevention against multidrug resistance possible?
Ratnasinghe D, Daschner PJ, Anver MR, Kasprzak BH, Taylor PR, Yeh GC, Tangrea JA. Ratnasinghe D, et al. Anticancer Res. 2001 May-Jun;21(3C):2141-7. Anticancer Res. 2001. PMID: 11501838 - Interleukin-6, multidrug resistance protein-1 expression and response to paclitaxel in women with metastatic breast cancer: results of cancer and leukemia group B trial 159806.
Rincon M, Broadwater G, Harris L, Crocker A, Weaver D, Dressler L, Berry D, Sutton L, Michaelson R, Messino M, Kirshner J, Fleming G, Winer E, Hudis C, Appel S, Norton L, Muss H; Cancer and Leukemia Group B. Rincon M, et al. Breast Cancer Res Treat. 2006 Dec;100(3):301-8. doi: 10.1007/s10549-006-9251-7. Epub 2006 Jun 14. Breast Cancer Res Treat. 2006. PMID: 16773437 Clinical Trial. - New silicon compounds as resistance modifiers against multidrug-resistant cancer cells.
Molnar J, Mucsi I, Nacsa J, Hevér A, Gyémánt N, Ugocsai K, Hegyes P, Kiessig S, Gaal D, Lage H, Varga A. Molnar J, et al. Anticancer Res. 2004 Mar-Apr;24(2B):865-71. Anticancer Res. 2004. PMID: 15161039 - The use of chemotherapy resistance in cancer treatment.
Deisseroth AB, Pizzorno G. Deisseroth AB, et al. Cancer J Sci Am. 1997 Mar-Apr;3(2):60-9. Cancer J Sci Am. 1997. PMID: 9099453 Review. No abstract available. - Regulation of interleukin-6 secretion from breast cancer cells and its clinical implications.
Kurebayashi J. Kurebayashi J. Breast Cancer. 2000;7(2):124-9. doi: 10.1007/BF02967443. Breast Cancer. 2000. PMID: 11029783 Review.
Cited by
- 1-Chromonyl-5-Imidazolylpentadienone Demonstrates Anti-Cancer Action against TNBC and Exhibits Synergism with Paclitaxel.
Modi K, Lawson S, Chen G, Tumuluri D, Rekhtman I, Kurtz M, Brailoiu GC, Chen QH, Lakshmikuttyamma A. Modi K, et al. Int J Mol Sci. 2020 Aug 12;21(16):5777. doi: 10.3390/ijms21165777. Int J Mol Sci. 2020. PMID: 32806551 Free PMC article. - Adipocyte‑rich microenvironment promotes chemoresistance via upregulation of peroxisome proliferator‑activated receptor gamma/ABCG2 in epithelial ovarian cancer.
Chen S, Liu Z, Wu H, Wang B, Ouyang Y, Liu J, Zheng X, Zhang H, Li X, Feng X, Li Y, Shen Y, Zhang H, Xiao B, Yu C, Deng W. Chen S, et al. Int J Mol Med. 2024 Apr;53(4):37. doi: 10.3892/ijmm.2024.5361. Epub 2024 Mar 1. Int J Mol Med. 2024. PMID: 38426604 Free PMC article. - AML‑derived mesenchymal stem cells upregulate CTGF expression through the BMP pathway and induce K562‑ADM fusiform transformation and chemoresistance.
Li H, Li J, Cheng J, Chen X, Zhou L, Li Z. Li H, et al. Oncol Rep. 2019 Sep;42(3):1035-1046. doi: 10.3892/or.2019.7237. Epub 2019 Jul 16. Oncol Rep. 2019. PMID: 31322275 Free PMC article. - Tumour necrosis factor and PI3-kinase control oestrogen receptor alpha protein level and its transrepression function.
Bhat-Nakshatri P, Campbell RA, Patel NM, Newton TR, King AJ, Marshall MS, Ali S, Nakshatri H. Bhat-Nakshatri P, et al. Br J Cancer. 2004 Feb 23;90(4):853-9. doi: 10.1038/sj.bjc.6601541. Br J Cancer. 2004. PMID: 14970864 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical
Molecular Biology Databases